Weather Advisory: Temporary Door Closure

Due to extreme cold, access through the Moakley Building's entrance off Boston Medical Center Place will be temporarily closed from 5 p.m. Friday, Jan. 30, through 7 a.m. Monday, Feb. 2.

All patients and visitors should use the main entrance for the Menino and Yawkey Buildings during this time. The hospital remains open and operating as normal.

We appreciate your patience as we take these precautions during severe winter weather.

Sprache

IRIS

IRIS: Insulin Resistance Intervention after Stroke Trial

Sponsor: NIH

Investigators: Carlos Kase MD (principal), Thanh Nguyen MD, Viken Babikian MD, Jose Romero MD, Aleksandra Pikula MD

Summary

Pioglitazone is a medication that improves insulin resistance, and is approved by the FDA for diabetes. Insulin resistance is a condition in which insulin, a normal human hormone, does not work effectively because the body is resistant to its effects. Insulin resistance can lead to diabetes and is thought to cause blood vessel disease, including stroke and heart attack in patients with and without diabetes. This study is designed to find out if a diabetes medication, pioglitazone, helps prevent recurrent stroke or heart attack among patients who have recently had a stroke or TIA.

Study enrollment completion in July 2015 and results pending.